Leap Therapeutics’ Owner Li William Boosts Stake with Massive RSU Settlement, Signaling Long‑Term Confidence in Dual Oncology‑Digital Asset Strategy

Insider Activity Highlights Leap Therapeutics’ Recent RSU Settlements

On March 13, 2026, Leap Therapeutics’ owner Li William executed a sizeable batch of restricted‑stock‑unit (RSU) settlements, converting a total of 168 750 shares into common stock. The transactions were driven by the vesting of two RSU grants—74 700 shares from a November 2025 grant and 94 050 shares from a December 2025 grant—each settled at a 1:1 ratio. The conversion did not involve any cash outlay; the shares were simply transferred into Li’s personal holdings, raising his post‑transaction stake to 168 750 shares.

What This Means for Investors and the Company’s Outlook

The immediate market impact was modest. At the time of settlement, the stock was trading near $0.79, a 0.13% increase from the previous close, and the move generated a social‑media buzz of 38.66 %—well below the industry average of 100 %. This suggests that, while insiders are accumulating equity, the broader market is not yet reacting strongly. For investors, the activity can be seen as a vote of confidence by a key stakeholder: Li is investing more of his own capital into the company without diluting shareholders, which may signal optimism about Leap’s pipeline and the expansion of its privacy‑technology platform.

From a strategic perspective, the RSU settlements align with Leap’s recent shift from oncology to a hybrid model that blends antibody therapeutics with a digital‑asset treasury centered on Zcash. Li’s increased ownership coincides with the company’s announcement of encouraging Phase 2 data for sirexatamab and the launch of a new Zcash‑based wallet. The timing hints that insiders are positioning themselves to benefit from both the clinical and digital‑asset upside, potentially foreshadowing future capital raises or strategic partnerships.

Profile of Li William: A Consistent Long‑Term Investor

Li’s insider trading history shows a pattern of disciplined RSU harvesting rather than speculative short‑term trades. Since late 2025, he has repeatedly converted RSUs into common shares at vesting dates, each time adding to his cumulative holding. His largest transaction—94 050 shares in December 2025—was followed by a rapid conversion in March 2026, illustrating a strategy of locking in gains while maintaining a long‑term position. Compared with other insiders, such as Martin Patricia A. and Joseph Loscalzo, Li’s trades are less frequent but larger in aggregate, indicating a commitment to the company’s long‑term trajectory.

Industry Context and Market Sentiment

Leap’s 2026 trading data shows a 39.74 % weekly gain and an 8.88 % monthly rise, yet its price remains low relative to a 52‑week high of $3.70. The company’s negative price‑earnings ratio of –0.52 reflects its status as a clinical‑stage biotech still working through regulatory milestones. In this environment, insider activity often signals confidence; Li’s recent RSU settlement is a subtle yet positive cue for investors watching the company’s dual focus on oncology and digital assets.

Takeaway for Investors

While the immediate price impact was minimal, Li William’s continued accumulation of shares—particularly through RSU conversions—demonstrates a measured, long‑term belief in Leap’s strategic direction. Investors may view this as a sign that key stakeholders are poised to support future growth initiatives, whether through additional capital, strategic alliances, or the eventual monetization of the company’s burgeoning digital‑asset portfolio.